WuXi AppTec, a global company providing a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) approved its near-term science-based emissions reduction targets.

With the SBTi validation, WuXi AppTec commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on 2024 levels. The company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities by 25% within the same timeframe.

“SBTi validation of WuXi AppTec’s near-term targets marks an important milestone in our Company’s sustainability journey,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee, in a statement. “This recognition underscores our commitment to corporate social responsibility, scientific rigor, and transparency of our greenhouse gas emission reduction efforts. WuXi AppTec is dedicated to supporting our customers in delivering innovative therapies to patients worldwide, working together toward a healthier and more sustainable future.”

To achieve these targets, WuXi AppTec, which has operations across Asia, Europe, and North America, is implementing measures such as process optimization, equipment upgrades, infrastructure renovation, and technological innovations to enhance energy efficiency.

The company is also increasing its use of renewable energy by purchasing green electricity and installing photovoltaic power generation facilities. These efforts aim to progressively reduce carbon emissions within operational boundaries. Furthermore, WuXi AppTec is collaborating with suppliers to reduce absolute GHG emissions associated with purchased goods and services, fostering progress toward a low-carbon supply chain.

To further its commitment to sustainability, WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner.